Vyluma Inc. announced that the National Medical Products Administration (NMPA) of China has accepted the drug application from Zhaoke Ophthalmology Limited for its lead compound, NVK002 (low-dose atropine 0.01%), as a potential treatment for myopia progression in children. NVK002, developed by Vyluma and licensed to Zhaoke, is a proprietary, investigational, preservative-free eye drop administered nightly, targeting pediatric patients with myopia. With its acceptance by the NMPA, NVK002 is now under regulatory review across three major global markets: the U.S., the European Union, and China.